Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Marcel Wacker
Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study
ArticlesOnline firstOpen access aClinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany bDepartment of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany cCluster of Excellence iFIT (EXC2180): Image-Guided and Functionally Instructed Tumor Therapies, University of Tübingen, Tübingen, Germany dGerman Cancer Consortium (DKTK), partner site Tübingen,...
EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation
|
ArticleOnline nowOpen access 1State Key Laboratory of Immune Response and Immunotherapy, Department of Neurology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, China 2Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland 3Cellerys AG, Wagistrasse 21, 8952 Schlieren, Switzerland 4Institute of Health...
By Jian Wang, Yuhan Qiu, Zoe Marti, Fengqi Li, Marcel Wacker, Pietro Oldrati, Lena Mühlenbruch, Linlin Jin, Hongxia Zhang, Wen Xu, Tingting Li, Bernd Roschitzki, Wolfgang Faigle, Yingjun Liu, Julie Nguyen, Jar-How Lee, Veronika Haunerdinger, Mathias Hauri-Hohl, Frank Momburg, Jens Bauer, Hans-Georg Rammensee, Mireia Sospedra, Roberta Magliozzi, Richard Reynolds, Juliane S. Walz, Roland Martin Verified
|
Cell Press
Verified
TAPBPR promotes editing of the HLA-B44 peptide repertoire, increasing the presentation of peptides containing a C-terminal tryptophan
|
1 Introduction Major histocompatibility complex class I (MHC-I) molecules play a crucial role in the adaptive immune response by presenting antigenic peptides typically derived from the intracellular proteome to CD8+ T cells (1, 2). Furthermore, the expression of MHC-I is monitored by natural killer (NK) cells for immunosurveillance (3, 4).
By Aure Aflalo, Marcel Wacker, Esam Khanfar, Jens Bauer, Juliane S. Walz, Louise Boyle Verified, Arwen F. Altenburg
|
Frontiers in Immunology
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification - Nature Communications
Abstract T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identification and characterization of naturally presented tumor-associated peptides, a key prerequisite for the development of T cell-based immunotherapies.
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency - Nature Communications
Abstract T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose.
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma - Nature
Abstract Microbial organisms have key roles in numerous physiological processes in the human body and have recently been shown to modify the response to immune checkpoint inhibitors1,2. Here we aim to address the role of microbial organisms and their potential role in immune reactivity against glioblastoma. We demonstrate that HLA molecules of both glioblastoma tissues and tumour cell lines present bacteria-specific peptides.
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma - Nature Communications
Abstract The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Marcel
Contact Marcel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack